Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inebilizumab with Steroid Tapering in Treatment-Naive NMOSD
NCT07159893Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2025
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Change in the average daily dose of corticosteroids at 24 weeks and Time to first clinical relapse at 24 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT07159893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159893.